Dr. David F. Mark

• 
  www.dddmag.com/ShowPR.aspx?PUBCODE=016&ACCT=1600000100& - [Cached Version]
  Published on: 3/31/2007    Last Visited: 3/31/2007  

  But confocal instruments are also by and large slower than their epifluorescence counterparts, says David Mark, PhD, senior research director, discovery technologies, Hoffmann-La Roche Inc., Nutley, N.J. Automated, high-resolution HCS remains a challenge, he says, and existing confocal devices are expensive.
  ...
  Roche researchers use the Explorer for primary screening and the Array Scan for secondary screening, says Mark, and have run several high-content screens on orphan GPCRs using the Transfluor assay from Xsira Pharmaceuticals Inc., Morrisville, N.C., formerly Norak Biosciences.One advantage of high-content assays, he says, is the ability to combine readouts of primary assays and secondary cytotoxicity assays.Roche's screening group has a series of assays to measure cytotoxicity, says Mark, which helps them flag or weed out potential problems, Mark says.

• 
  www.lifesciencesinfo.com/cod/oinfo_lower.asp?pid=USC317 - [Cached Version]
  Published on: 12/11/2004    Last Visited: 2/20/2006  

  David Mark, Ph.D., Global Head, High Throughput Screening, Hoffman-La Roche, Inc.

• 
  ww.healthtech.com/2003/gpc/index.asp - [Cached Version]
  Published on: 1/1/2003    Last Visited: 3/1/2007  

  Dr. David F. Mark, Hoffmann-La Roche, Inc.
  ...
  Dr. David F. Mark, Senior Research Director, Roche Discovery Technologies, Hoffmann-La Roche, Inc.

• 
  www.ipo.org/Template.cfm?Section=Home&Template=/Content - [Cached Version]
  Published on: 1/11/2005    Last Visited: 4/13/2006  

  1986 - Leo S. Lin, Shji-Da Yu Lu, and David F. Mark - Cetus Corp. - "Cetus Interleukin-2", a genetically engineered drug.

• 
  2004 GRC on Medicinal Chemistry - [Cached Version]
  Published on: 7/14/2004    Last Visited: 12/11/2004  

  David Mark (Roche)"Strategy for Identifying and Validating Orphan GPCRs as Drug Discovery Targets"

• 
  CEA Content - [Cached Version]
  Published on: 6/25/2008    Last Visited: 6/25/2008  

  David Mark ,Ph.D.Chairman
  ...
  David Mark, Ph.D. Dr. Mark is currently head of the High Throughput Screening at Hoffmann-La Roche.In this capacity, he is responsible for identifying new chemical leads for all projects in Preclinical Research & Development at the Nutley, New Jersey site.David earned his Bachelor s degree in Chemistry at the University of Massachusetts (1973, Summa Cum Laude) and his Ph.D. in Biochemistry at Harvard Medical School (1977), where he worked with Dr. Charles Richardson on bacteriophage T7 DNA replication.He accepted a postdoctoral position at Stanford University Medical Center, Department of Biochemistry in the laboratory of Dr. Paul Berg (1977-79).He then spent ten years with Cetus Corporation, moving into positions of increasing responsibility in the Molecular Biology and New Therapeutics areas.In 1989, David accepted the Executive Director position at Merck & Co., and in the following ten years was responsible for various drug discovery programs, including Natural Products Discovery and Growth Factor Mimetics.
  
  David has made several major contributions to science and medicine.He developed a novel modified Interleukin-2 recombinant protein for the treatment of renal cancer and melanoma.He also played a significant role in the development of a genetically modified Fibroblast Interferon for the treatment of Multiple Sclerosis.David also developed and patented a novel method for the quantitation of messenger RNA levels in single cells using a modification of the polymerase chain reaction.
  
  David has published over 30 papers and holds 19 patents.He has been invited to present at numerous scientific meetings.David is the recipient of the Outstanding Young Scientist in America Award given by Science Digest Magazine (1984).He also received the Inventor of the Year Award (1986) given by Intellectual Properties Owners, Inc., for his role in the development of the genetically-engineered Interleukin-2 Muteins.He was a member of the Program Advisory Committee of the Biotechnology Research Institute, The Hong Kong University of Science and Technology (1990-93); and he was appointed as a Scientific Advisor of the China National Center for Biotechnology Development, Beijing, China (1984-87).

• 
  CHI's GPCRs From Orphan to Blockbuster - [Cached Version]
  Published on: 9/4/2002    Last Visited: 8/25/2003  

  Dr. David F. Mark, Hoffmann-La Roche, Inc.
  ...
  Dr. David F. Mark, Senior Research Director, Roche Discovery Technologies, Hoffmann-La Roche, Inc.

• 
  Drug Discovery & Development - [Cached Version]
  Published on: 11/6/2006    Last Visited: 11/6/2006  

  David Mark, PhD, senior research director for Roche Discovery Technologies, Nutley, N.J., believes the most effective nanoliter dispensers on the market are made by Cartesian Dispensing Systems (acquired by Genomic Solutions in 2001), Ann Arbor, Mich.; Caliper (formerly Zymark) in Hopkinton, Mass.; and CyBio, in Woburn, Mass. "These, to us, are probably the most advanced and more unique and versatile systems of nanoliter pipetting or nanoliter dispensing," says Mark.
  
  "The problem with nanoliter dispensing is that, because of the small volume, it has to be very accurate.The valves that are used for this work have to be very well engineered and deliver liquid very accurately and reproducibly.Some of the systems out there from other companies don't work as well as these three."Each company has a different approach to building the dispensing heads and has developed some way of measuring or calibrating them to ensure that each valve is dispensing the same volume, even at very low levels.Traditional 96- and 384-well pipetters, for example, cannot deliver accurately below one microliter, but the better nanoliter dispensers can deliver accurately down to the 10- to 50-nanoliter range, Mark says.
  
  Roche is integrating a device called the NanoJet into its ultra high-throughput screening system and anticipates cutting reagent use by at least 30%.Roche worked with CyBio to develop the NanoJet, a noncontact dispenser that can deliver volumes ranging from 50 nanoliters to 20 microliters.The NanoJet features ceramic nozzles designed by Roche scientists in Switzerland that were licensed to CyBio.Mark says Roche decided to develop the system with CyBio after concluding that ones from Caliper and Cartesian Dispensing Systems did not meet their specifications.

• 
  Drug Discovery & Development - [Cached Version]
  Published on: 8/4/2005    Last Visited: 8/4/2005  

  "That often creates a lot of problems when you're trying to get different pieces of equipment to work together," says David Mark, PhD, senior research director of discovery technologies at Hoffmann-La Roche Inc., Nutley, N.J. "If you can buy off-the-shelf systems, that would be the best way to go."
  ...
  Mark says he has also witnessed people trying to perform automated assays in the same way that they do them by hand.

• 
  Drug Discovery & Development - [Cached Version]
  Published on: 1/13/2005    Last Visited: 1/13/2005  

  David Mark, PhD, senior research director for Roche Discovery Technologies, Nutley, N.J., believes the most effective nanoliter dispensers on the market are made by Cartesian Dispensing Systems (acquired by Genomic Solutions in 2001), Ann Arbor, Mich.; Caliper (formerly Zymark) in Hopkinton, Mass.; and CyBio, in Woburn, Mass. "These, to us, are probably the most advanced and more unique and versatile systems of nanoliter pipetting or nanoliter dispensing," says Mark.
  
  "The problem with nanoliter dispensing is that, because of the small volume, it has to be very accurate.The valves that are used for this work have to be very well engineered and deliver liquid very accurately and reproducibly.Some of the systems out there from other companies don't work as well as these three."Each company has a different approach to building the dispensing heads and has developed some way of measuring or calibrating them to ensure that each valve is dispensing the same volume, even at very low levels.Traditional 96- and 384-well pipetters, for example, cannot deliver accurately below one microliter, but the better nanoliter dispensers can deliver accurately down to the 10- to 50-nanoliter range, Mark says.
  
  Roche is integrating a device called the NanoJet into its ultra high-throughput screening system and anticipates cutting reagent use by at least 30%.Roche worked with CyBio to develop the NanoJet, a noncontact dispenser that can deliver volumes ranging from 50 nanoliters to 20 microliters.The NanoJet features ceramic nozzles designed by Roche scientists in Switzerland that were licensed to CyBio.Mark says Roche decided to develop the system with CyBio after concluding that ones from Caliper and Cartesian Dispensing Systems did not meet their specifications.

Page:  1 2